"Rifampin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
| Descriptor ID |
D012293
|
| MeSH Number(s) |
D03.633.400.811.700 D04.345.295.750.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Rifampin".
Below are MeSH descriptors whose meaning is more specific than "Rifampin".
This graph shows the total number of publications written about "Rifampin" by people in this website by year, and whether "Rifampin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 2 | 3 |
| 1997 | 2 | 0 | 2 |
| 1998 | 3 | 1 | 4 |
| 1999 | 1 | 2 | 3 |
| 2001 | 1 | 0 | 1 |
| 2002 | 4 | 3 | 7 |
| 2003 | 4 | 2 | 6 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 4 | 5 |
| 2009 | 2 | 3 | 5 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 4 | 5 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 5 | 6 |
| 2016 | 6 | 2 | 8 |
| 2017 | 3 | 5 | 8 |
| 2018 | 1 | 2 | 3 |
| 2019 | 2 | 1 | 3 |
| 2020 | 3 | 5 | 8 |
| 2021 | 0 | 3 | 3 |
| 2022 | 1 | 5 | 6 |
| 2023 | 0 | 4 | 4 |
| 2024 | 1 | 6 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rifampin" by people in Profiles.
-
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response. Clin Microbiol Infect. 2024 Sep; 30(9):1207-1208.
-
Antistreptococcal treatment of psoriasis: a systematic review. Arch Dermatol Res. 2024 Jun 08; 316(7):363.
-
Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland. Respiration. 2024; 103(9):593-600.
-
Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024 Aug 01; 102(8):600-607.
-
Multidrug-resistant tuberculosis. Nat Rev Dis Primers. 2024 Mar 24; 10(1):22.
-
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe. Clin Microbiol Infect. 2024 Sep; 30(9):1197.e1-1197.e4.
-
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nat Med. 2024 Mar; 30(3):896-904.
-
[Treatment of MDR, pre-XDR, XDR and rifampicin resistant tuberculosis or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment dated 19.09.2023 to the Sk2-Guideline: Tuberculosis in adulthood of the German Central Committee against Tuberculosis (DZK) on behalf of the German Respiratory Society (DGP)]. Pneumologie. 2024 Jan; 78(1):35-46.
-
Detection of Genes Encoding Microbial Surface Component Recognizing Adhesive Matrix Molecules in Methicillin-Resistant Staphylococcus aureus Isolated from Pyoderma Patients. Genes (Basel). 2023 03 24; 14(4).
-
Gene network interaction analysis to elucidate the antimicrobial resistance mechanisms in the Clostridiumdifficile. Microb Pathog. 2023 May; 178:106083.